Enhanced collaboration with the US on med tech regulation, with accelerated innovation, strengthened patient safety, and reduced transatlantic barriers to market access.
Similar Posts
Class 2 Medicines Recall: Fucidin 250 mg Tablets, LEO Laboratories Ltd trading as LEO Pharma, EL(25)A/38
LEO Pharma is recalling the affected batch as a precautionary measure due to out of specification results for impurities during routine stability testing.
Chikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measure
This is a precautionary measure while the MHRA conducts the safety review.
Apply for a licence to market a medicine in the UK
An overview of the process including submitting or fast-tracking an application, naming your medicine and paying fees.
Guidance: Get more help to apply for medicines Integrated Scientific Advice (ISA)
Extra information for the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) Integrated Scientific Advice (ISA) service.
Class 4 Medicines Defect Notification: Ipca Laboratories UK Limited, Various Products, EL(25)A/42
Ipca Laboratories UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the products listed in this notification do not contain all the required safety information.
Guidance: Report on Adverse Event (AE) reporting in digital mental health technologies (DMHTs) and the development of updates to regulatory guidance
Advice for manufacturers of DMHTs that qualify as software as a medical device (SaMD) on understanding new post marketing surveillance rules and examples of how they apply.